Options
Single‐Use Bioreactors for Manufacturing of Immune Cell Therapeutics
Publikationstyp
Book Part
Date Issued
2019
Sprache
English
Author(s)
Institut
TORE-URI
Start Page
327
End Page
334
Citation
Single‐Use Technology in Biopharmaceutical Manufacture, Second Edition, John Wiley & Sons, Inc.:327-334 (2019)
Publisher DOI
Publisher
John Wiley & Sons, Inc.
This chapter provides an overview of more or less advanced technologies and devices available for manufacturing immune cell therapeutics. When manufacturing therapeutic doses of a personal immune cell advanced therapy medicinal product, it has to be considered that only some subsets of the total immune cell mixture taken from a patient sample is able to recognize mutated tumor cells or other disease‐causing cells. Single‐use devices are predominant in the production of immune cells at clinically relevant doses. The ZRP platform of Zellwerk and its bioreactor types provides sophisticated features not only for mass production of different immune cells but also for realizing isolation and culturing the cells in closed processes. Bioreactors of the ZRP system can be operated in the good manufacturing practice (GMP) breeder. The cell‐cultivation platform's single‐use bioreactors enable the manufacturing of large quantities of individual immune cell preparations under GMP conditions.